- Home
- BIIB vs JBHT Comparison
BIIB vs JBHT Comparison
Compare BIIB & JBHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- JBHT
- Stock Information
- Founded
- BIIB 1978
- JBHT 1961
- Country
- BIIB United States
- JBHT United States
- Employees
- BIIB N/A
- JBHT N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- JBHT Trucking Freight/Courier Services
- Sector
- BIIB Health Care
- JBHT Industrials
- Exchange
- BIIB Nasdaq
- JBHT Nasdaq
- Market Cap
- BIIB 18.7B
- JBHT 15.7B
- IPO Year
- BIIB 1991
- JBHT N/A
- Fundamental
- Price
- BIIB $154.27
- JBHT $168.86
- Analyst Decision
- BIIB Buy
- JBHT Buy
- Analyst Count
- BIIB 22
- JBHT 18
- Target Price
- BIIB $174.11
- JBHT $168.72
- AVG Volume (30 Days)
- BIIB 1.5M
- JBHT 1.7M
- Earning Date
- BIIB 10-30-2025
- JBHT 10-15-2025
- Dividend Yield
- BIIB N/A
- JBHT 1.04%
- EPS Growth
- BIIB N/A
- JBHT 5.00
- EPS
- BIIB 10.97
- JBHT 5.77
- Revenue
- BIIB $10,065,900,000.00
- JBHT $12,048,818,000.00
- Revenue This Year
- BIIB $2.03
- JBHT $1.34
- Revenue Next Year
- BIIB N/A
- JBHT $3.80
- P/E Ratio
- BIIB $14.06
- JBHT $29.24
- Revenue Growth
- BIIB 4.77
- JBHT N/A
- 52 Week Low
- BIIB $110.04
- JBHT $122.79
- 52 Week High
- BIIB $179.48
- JBHT $200.40
- Technical
- Relative Strength Index (RSI)
- BIIB 64.58
- JBHT 67.22
- Support Level
- BIIB $138.00
- JBHT $164.57
- Resistance Level
- BIIB $151.91
- JBHT $171.52
- Average True Range (ATR)
- BIIB 4.62
- JBHT 4.69
- MACD
- BIIB 0.21
- JBHT 0.75
- Stochastic Oscillator
- BIIB 94.70
- JBHT 89.89
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).